Antibody-drug Conjugate As Targeted Therapeutics Against Hepatocellular Carcinoma: Preclinical Studies and Clinical Relevance

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2021 Oct 1

PMID 34595736

Citations 6

Authors

M Murali

A R Kumar

B Nair

K Pavithran

A R Devan

G K Pradeep

L R Nath

Affiliations

Soon will be listed here.

Abstract

An antibody-drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal antibody for site-directed delivery and cytotoxic payload for targeted destruction of malignant cells. Therefore, it enables the reduction of off-target toxicities and enhances the therapeutic index of the drug. Hepatocellular carcinoma (HCC) is a solid tumor that shows high heterogeneity of molecular phenotypes and is considered the second most common cause of cancer-related death. Studies show enormous potential for ADCs targeting GPC3 and CD24 and other tumor-associated antigens in HCC with their high, selective expression and show potential outputs in preclinical evaluations. The review mainly highlights the preclinical evaluation of different antigen-targeted ADCs such as MetFab-DOX, Anti-c-Met IgG-OXA, Anti CD 24, ANC-HN-01, G7mab-DOX, hYP7-DCand hYP7-PC, Anti-CD147 ILs-DOX and AC133-vcMMAF against hepatocellular carcinoma and its future relevance.

Citing Articles

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.

Insights in Molecular Therapies for Hepatocellular Carcinoma.

Heumann P, Albert A, Gulow K, Tumen D, Muller M, Kandulski A Cancers (Basel). 2024; 16(10).

PMID: 38791911 PMC: 11120383. DOI: 10.3390/cancers16101831.

Checkpoint CD24 function on tumor and immunotherapy.

Huang S, Zhang X, Wei Y, Xiao Y Front Immunol. 2024; 15:1367959.

PMID: 38487533 PMC: 10937401. DOI: 10.3389/fimmu.2024.1367959.

Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche.

de Oliveira K, Bang-Rudenstam A, Beyer S, Boukredine A, Talbot H, Governa V Acta Neuropathol Commun. 2024; 12(1):35.

PMID: 38414005 PMC: 10898066. DOI: 10.1186/s40478-024-01740-z.

Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma.

Li Z, Zhang Z, Fang L, Zhao J, Niu Z, Chen H J Hepatocell Carcinoma. 2023; 10:2083-2099.

PMID: 38022729 PMC: 10676104. DOI: 10.2147/JHC.S436962.

References

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M . Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019; 18(2):291-297. DOI: 10.1016/j.aohep.2019.04.003. View

Nishida N, Kudo M . Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. Oncology. 2017; 93 Suppl 1:160-164. DOI: 10.1159/000481246. View

Nishida N, Kudo M . Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. Oncology. 2016; 92 Suppl 1:40-49. DOI: 10.1159/000451015. View

Sachdeva M, Chawla Y, Arora S . Immunology of hepatocellular carcinoma. World J Hepatol. 2015; 7(17):2080-90. PMC: 4539401. DOI: 10.4254/wjh.v7.i17.2080. View

Makarova-Rusher O, Medina-Echeverz J, Duffy A, Greten T . The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015; 62(6):1420-9. DOI: 10.1016/j.jhep.2015.02.038. View

Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K . Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10(2):99-111. DOI: 10.1016/j.ccr.2006.06.016. View

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C . Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology. 2016; 64(6):2038-2046. DOI: 10.1002/hep.28710. View

Greten T, Lai C, Li G, Staveley-OCarroll K . Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):510-524. PMC: 6340758. DOI: 10.1053/j.gastro.2018.09.051. View

10.

Pinter M, Scheiner B, Peck-Radosavljevic M . Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2020; 70(1):204-214. PMC: 7788203. DOI: 10.1136/gutjnl-2020-321702. View

11.

Lu L, Hsu C, Hsu C, Cheng A . Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer. 2016; 5(2):128-38. PMC: 4906428. DOI: 10.1159/000367754. View

12.

Ghouri Y, Mian I, Rowe J . Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017; 16:1. PMC: 5490340. DOI: 10.4103/jcar.JCar_9_16. View

13.

Kumari R, Sahu M, Tripathy A, Uthansingh K, Behera M . Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat Oncol. 2019; 5(2):HEP08. PMC: 6613045. DOI: 10.2217/hep-2018-0002. View

14.

Bailly C, Thuru X, Quesnel B . Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2021; 2(1):zcaa002. PMC: 8209987. DOI: 10.1093/narcan/zcaa002. View

16.

Peters C, Brown S . Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015; 35(4). PMC: 4613712. DOI: 10.1042/BSR20150089. View

17.

Gerber H, Koehn F, Abraham R . The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep. 2013; 30(5):625-39. DOI: 10.1039/c3np20113a. View

18.

Chari R, Miller M, Widdison W . Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(15):3796-827. DOI: 10.1002/anie.201307628. View

19.

Lambert J, Morris C . Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv Ther. 2017; 34(5):1015-1035. PMC: 5427099. DOI: 10.1007/s12325-017-0519-6. View

20.

Perez-Herrero E, Fernandez-Medarde A . Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015; 93:52-79. DOI: 10.1016/j.ejpb.2015.03.018. View

21.

Schrama D, Reisfeld R, Becker J . Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006; 5(2):147-59. DOI: 10.1038/nrd1957. View